Valuable predictive features of relapse of XXXX after antithyroid drug treatment.

@entity1 @entity3937 @entity2743 @entity1955 @entity3214 @entity5651 @entity6875 @entity1954
PURPOSE: Antithyroid drug treatment (ATDT) effectively achieves @entity3214 in @entity1 with @entity2743 ( @entity2743 ). However, apparently successful treatment may be followed by relapse. We investigated the outcome of ATDT in Chinese @entity1 with @entity2743 to identify predictive features of relapse. METHODS: In total, 133  @entity1 with mild to moderate @entity5651 were included in this analysis. All @entity1 received @entity3937 for 12 to 40months and were subsequently followed up for at least 1year. Lasting remission was defined as the presence of clinical and laboratory features of @entity3214 for>= 1year after stopping @entity3937 . RESULTS: Most @entity1 (118 of 133, 88.7%) remained in remission after the follow-up period; 15  @entity1 (11.3%) developed relapse. A history of @entity2743 , larger @entity5651 at the time of drug withdrawal, a positive thyroid-stimulating antibody titer and restauration of low thyroid-stimulating hormone levels during the maintenance period were related to a subsequent risk of relapse according to stepwise logistic regression analysis results. However, other clinical and biological features (age, sex, initial @entity5651 , @entity6875 , @entity1955 and @entity1954 levels and thyroglobulin antibody and thyroid microsomal antibody titers) did not reach statistical significance. CONCLUSION: Regular, individualized ATDT achieved an 88.7% remission rate in Chinese @entity1 with @entity2743 . The features associated with probable relapse were a history of @entity2743 , larger @entity5651 at the time of drug withdrawal, a positive thyroid-stimulating antibody titer at the time of drug withdrawal and redevelopment of low thyroid-stimulating hormone levels during the maintenance period.
